Shares of BioCryst Pharmaceuticals took a beating this morning after the company announced it was halting the intravenous drug arm of a cancer trial after finding particles in the treatment solution. Shares slipped 11 percent on the news that researchers had found particles in batches of Fodosine during a cancer trial. Early tests indicated that the particles came from the stopper used in packaging the drug and that it would not have a contaminating effect. The company alerted the FDA and suspended enrollment and treatment. Patients taking an oral version of Fodosine will continue in the trial.
- see this release from BioCryst
- read the AP report
BioCryst seeks approval for flu trial, signs deal with Roche. Report
BioCryst gets fast-track status for avian flu drug. Report
BioCryst shares peak on hopes for bird flu drug. Report